

Data Sheet

Product Name:	BML-277	
Cat. No.:	CS-1809	
CAS No.:	516480-79-8	
Molecular Formula:	C ₂₀ H ₁₄ CIN ₃ O ₂	
Molecular Weight:	363.80	
Target:	Apoptosis; Checkpoint Kinase (Chk)	
Pathway:	Apoptosis; Cell Cycle/DNA Damage	
Solubility:	DMSO : 22.22 mg/mL (61.08 mM; Need ultrasonic)	

BIOLOGICAL ACTIVITY:

BML-277 is a selective checkpoint kinase 2 (**Chk2**) inhibitor with an **IC**₅₀ of 15 nM. IC50 & Target: IC50: 15 nM (Chk2)^[1] *In Vitro:* BML-277 is an ATP-competitive inhibitor of Chk2 that dose dependently protects human CD4⁺ and CD8⁺ T-cells from apoptosis due to ionizing radiation. BML-277 efficiently rescues both T-cell populations from radiation-induced apoptosis in a dose-dependent manner with an observed EC₅₀ of 3–7.6 μ M. The concentration of BML-277 required for radioprotection is consistent with the biochemical measurement of chk2 inhibition. Providing theK_m of ATP for Chk2 is determined to be 99 μ M and the K_i for BML-277 is 37 nM, and assuming that the intracellular ATP concentration is 10 mM, a 5 μ M concentration of BML-277 would be expected to produce 42% inhibition of intracellular chk2^[1].

PROTOCOL (Extracted from published papers and Only for reference)

Kinase Assay: ^[1]Activity of inhibitors of chk2 is determined by incubating inhibitory compounds with recombinant full-length chk2: 5 nM recombinant human Chk2, 50 mM HEPES (pH 7.4), 100 mM NaCl, 10 mM MgCl₂, 25 µM synthetic peptide substrate (biotin-SGLYRSPSMPENLNRPR, 1 µM ATP, 50 µCi/mL [y-33P] ATP, and a protease inhibitor mixture. The reaction mixtures are incubated at 37°C for 3 h, and the peptide substrate is captured on streptavidin conjugated to agarose beads. The agarose beads are washed repeatedly with a 0.1% solution of Tween-20 in phosphate-buffered saline, pH 7.4. Enzyme activity at different BML-277 concentrations (6.25, 12.5, 25, 50, 100, and 200 nM) is determined by measuring the amount of radioactive phosphate bound to the substrate peptide by scintillation counting. In kinetic experiments ATP concentration is varied while the ratio between unlabeled and [γ -³³P] labeled ATP is kept constant. Reactions are stopped at different time points by addition of 50 mM cold ATP and samples are kept on ice during further processing^[1]. Cell Assay: BML-277 is dissolved in DMSO and stored, and then diluted with appropriate medium before use^{[1],[1]}To determine the radioprotective effect of Chk2 inhibitors, purified T-cells are incubated at 100 000 cells per well in BML-277 (10^{2.5} nM, 1 µM, 10^{0.5} µM, 10 µM, and 10^{1.5} µM) or vehicle (DMSO) at varying concentrations in 96-well stripwells for 1 h. Cells are then exposed to a dose of 0 or 10 Gy gamma irradiation from a ¹³⁷Cs source at a dose rate of 3.65 Gy/min and then returned to the incubator for a further 24 h. Cells are stained with Annexin V-FITC and propidium iodide, according to the manufacturers protocol. Apoptotic and surviving cells are quantitated with a FACSCalibur FACS machine. Data are reported as percent recovery-or the number of survivors from treatment groups minus the number of cells surviving in the irradiated control group divided by the number of surviving cells in the untreated control groups^[1].

References:

[1]. Arienti KL, et al. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005 Mar 24;48(6):1873-85.

CAIndexNames:

1H-Benzimidazole-6-carboxamide,2-[4-(4-chlorophenoxy)phenyl]-

SMILES:

CIC(C=C1)=CC=C1OC(C=C2)=CC=C2C3=NC4=CC(C(N)=O)=CC=C4N3

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128	Fax: 888-484-5008	E-mail: sales@ChemScene.com
Address: 1	Deer Park Dr, Suite Q, Monmouth	Junction, NJ 08852, USA